In the HER2CLIMB trial, patients with HER2+ metastatic breast cancer, who had received at least two prior anti-HER2–directed regimens, reported preservation of overall HR-QoL when tucatinib was added to a trastuzumab and capecitabine regimen. Importantly, this durability of HR-QoL throughout the...
She was definitely shutting that conversation down before it could get started. She’s not wrong--the schedule is indeed the schedule when it comes to Herceptin (trastuzumab) and its biosimilars. There is no information on “de-escalating” treatment by extending the time between doses. Every ...
In an interim analysis of the trial, invasive disease or death occurred in 91 patients in the 743-patient T-DM1 group (12.2%) and 165 patients in the 743-patient trastuzumab group (22.2%). The estimated percentage of patients free of invasive disease at 3 years was 88.3% in the T-DM1 ...
Moreover, bevacizumab in combination with capecitabine was approved as first-line treatment of MBC patients for whom therapy with other chemotherapy regimens, including those based on taxanes or anthracyclines, was not considered appropriate. Nevertheless, in November 2011, the FDA announced that breast...
“In this study, we found that the adverse impact of a second cancer on survival was most pronounced in children and AYAs compared with older adults.” The researchers saw significant differences in survival among the common cancer types. For instance, AYA patients diagnosed with AML as...